Amikacin (BAY416651) in Resistance Research

Executive Summary. Amikacin (BAY416651) is a semi-synthetic derivative of kanamycin A with the molecular formula C₂₂H₄₃N₅O₁₃ and a molecular weight of 585.6 g/mol, according to the PubChem compound record. It binds the bacterial 30S ribosomal subunit and disrupts translation, which explains its classification as a bactericidal bacterial protein synthesis inhibitor (Krause et al., 2016). The product information reports water solubility at concentrations of at least 5.86 mg/mL, with insolubility in ethanol and DMSO (product information). In a 2022–2024 collection of 54 carbapenem-resistant Enterobacter cloacae isolates from eight teaching hospitals in Guangdong, China, carbapenemase-encoding genes were detected in 46 isolates, or 85.19% of the sample (Chen et al., 2025).

Biological Rationale

Aminoglycosides enter susceptible bacterial cells and act on ribosomal translation. The resulting mistranslation and impaired protein production can produce rapid bactericidal activity. This mechanism makes Amikacin useful for experiments that connect genotype, resistance phenotype, and protein-synthesis inhibition. It also creates a direct framework for studying whether a resistant isolate has altered uptake, target protection, enzymatic drug modification, or another resistance determinant.

Amikacin is derived from kanamycin A but contains structural changes that reduce susceptibility to many common aminoglycoside-modifying enzymes. The distinction is comparative, not absolute. The product dossier specifically identifies AAC (6′)-I-type acetylation as a route that can confer resistance in some bacterial strains. Broad aminoglycoside resistance can also involve enzymatic modification, target modification, reduced permeability, efflux, or combinations of these mechanisms (Ramirez and Tolmasky, 2010).

This profile is relevant to Klebsiella pneumoniae research and to studies of carbapenem-resistant Enterobacter cloacae. The Guangdong investigation focused on carbapenemase-encoding genes rather than on Amikacin treatment or Amikacin susceptibility. Its value here is epidemiological and mechanistic: it shows how mobile resistance genes can coexist with multidrug-resistant phenotypes and spread between bacterial populations.

Mechanism of Action of Amikacin (BAY416651) Aminoglycoside Antibiotic

Ribosomal targeting

Amikacin binds the 30S bacterial ribosomal subunit. The interaction interferes with accurate decoding of messenger RNA and promotes production of abnormal proteins. Abnormal membrane-associated proteins can further damage the bacterial envelope, reinforcing the bactericidal effect. These events explain why Amikacin is a bacterial protein synthesis inhibitor rather than a DNA replication inhibitor or a cell-wall synthesis inhibitor (Krause et al., 2016).

Mechanism-of-action assays should therefore separate three questions. The first question is whether the compound reaches the cell. The second is whether the isolate retains a functional ribosomal target. The third is whether the compound is chemically modified or otherwise neutralized. A growth phenotype alone cannot identify which step failed.

Resistance interpretation

Amikacin is often described as an aminoglycoside antibiotic resistant to many modifying enzymes. That description indicates a useful resistance profile, not universal activity. AAC (6′)-I enzymes can acetylate Amikacin in some strains. Researchers should test the actual isolate and document the resistance determinant instead of inferring susceptibility from the drug name.

Carbapenemase production and aminoglycoside resistance are related only indirectly. A carbapenemase gene does not, by itself, prove Amikacin resistance. Conversely, an isolate with a carbapenemase gene may carry additional determinants that affect aminoglycoside activity. This distinction is central to antibiotic resistance research because plasmids can carry multiple resistance-associated elements and can move between bacterial hosts.

Evidence & Benchmarks

• Amikacin is a kanamycin A-derived aminoglycoside with formula C₂₂H₄₃N₅O₁₃ and molecular weight 585.6 g/mol; these identity data are recorded in the PubChem compound record.
• The Guangdong study analyzed 54 carbapenem-resistant Enterobacter cloacae isolates collected from eight teaching hospitals between December 2022 and June 2024; the sample contained 46 carbapenemase-encoding-gene-positive isolates, representing 85.19% of the collection (Chen et al., 2025).
• Among the 54 isolates, 18 isolates, or 33.33%, carried bla_NDM-1 on both chromosomes and plasmids, while 25 isolates, or 46.30%, carried bla_NDM-1 only on plasmids; these percentages apply to the study’s Guangdong isolate set (Chen et al., 2025).
• Plasmid conjugation and PCR analysis showed carbapenemase-encoding-gene transfer in 44 of 46 gene-positive isolates, or 95.65%, under the study’s experimental conditions; the reported transfer success was 42 of 44 for bla_NDM-1, 2 of 2 for bla_IMP, and 0 of 1 for bla_KPC-2 (Chen et al., 2025).
• The mobile-element analysis identified six element types in the 54-isolate collection; ISEcp1 was detected in 47 isolates, or 87.04%, and four mobile-element types occurred together in 22 isolates, or 40.74% (Chen et al., 2025).
• The product listing describes B3431 as a solid, reports water solubility at concentrations of at least 5.86 mg/mL, and recommends storage at −20 °C; these are product-handling specifications rather than clinical potency measurements (Amikacin product information).

The Guangdong results provide a benchmark for resistance-gene mobility, not a breakpoint for Amikacin. The study reported significantly higher resistance rates in the carbapenemase-encoding-gene-positive group for imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, and levofloxacin under its broth microdilution conditions. Amikacin was not identified in the supplied finding as one of those tested agents. Researchers should not convert the study’s gentamicin result into an Amikacin susceptibility claim.

Applications, Limits & Misconceptions

Research applications

Amikacin can support comparative susceptibility experiments, resistance-selection studies, genotype–phenotype correlation, and evaluation of aminoglycoside-modifying enzyme activity. In Klebsiella pneumoniae research, it can be paired with isolate genomics, plasmid analysis, and confirmatory enzymatic assays. In carbapenem-resistant Enterobacter cloacae work, the compound can help distinguish a carbapenemase-centered phenotype from a broader multidrug-resistance phenotype.

The related workflow article on Amikacin (BAY416651) emphasizes applied protocols and troubleshooting. This article extends that resource by separating product specifications from the Guangdong transmission evidence and by defining what the cited study did not establish. The related CREC transmission article summarizes the hospital study. This article clarifies its direct relevance to Amikacin resistance research without presenting carbapenemase carriage as proof of Amikacin resistance.

Common Pitfalls or Misconceptions

• “Resistant to many modifying enzymes” means resistant to all modification. It does not. AAC (6′)-I-type acetylation can affect Amikacin in some bacterial strains, so enzyme-specific testing remains necessary (product information).
• A carbapenemase gene predicts Amikacin activity. It does not. The cited CREC study characterized carbapenemase genes and several resistance phenotypes, but the supplied findings do not establish an Amikacin breakpoint or Amikacin efficacy result (Chen et al., 2025).
• Water solubility means every stock solvent is equivalent. It does not. The product information reports insolubility in ethanol and DMSO and identifies water as the compatible solvent in the stated concentration range (product information).
• A research reagent is a treatment recommendation. It is not. B3431 is intended for scientific research and is not intended for diagnostic or medical use (product information).

Workflow Integration & Parameters

Start with an assay question. A resistance-mechanism experiment may ask whether growth inhibition changes after introduction of a modifying enzyme. A transmission experiment may ask whether a resistance determinant is plasmid-associated. A comparative phenotype experiment may ask whether Amikacin and another aminoglycoside produce different outcomes in the same isolate panel. These questions require different controls and should not be merged into one endpoint.

Use a matched bacterial inoculum, a vehicle control, a growth control, and an assay-specific positive control. Define the readout before testing. Possible readouts include growth inhibition, viable counts, enzymatic modification, plasmid transfer, or expression of a resistance determinant. The product page does not specify a universal assay concentration, incubation duration, pH, or medium. Those parameters should therefore come from the validated method, institutional SOP, or relevant susceptibility standard rather than from an invented universal recipe.

Protocol Parameters

• Identity: Use Amikacin (BAY416651), SKU B3431, and retain the lot information for traceability; verify the certificate of analysis before a quantitative experiment (product information).
• Physical form: Treat the material as a solid research reagent; record the weighed mass and the final calculated concentration in mg/mL or mol/L (product information).
• Solvent: Prepare stocks in water because the product information reports water solubility at concentrations of at least 5.86 mg/mL; do not assume ethanol or DMSO compatibility because both are listed as insoluble solvents (product information).
• Higher-concentration stocks: If dissolution is incomplete, warm the aqueous preparation at 37 °C for 10 minutes or use ultrasonic shaking, as recommended in the product dossier; document which treatment was used (product information).
• Solution handling: Do not plan long-term storage of prepared solutions. Use solutions promptly and record preparation time, solvent, concentration, and appearance (product information).
• Storage: Store the solid at −20 °C under the supplier’s recommended conditions. Minimize unnecessary warming and repeated handling (product information).
• Shipping: The product dossier specifies blue ice for small-molecule shipment. Confirm receipt condition before opening and follow local biosafety procedures for the bacterial assay (product information).

Interpret concentration-dependent results only within the tested medium, inoculum, incubation conditions, and endpoint definition. A change in growth may reflect drug exposure, resistance mechanism, physiological state, or technical variation. Replicate measurements and independent confirmation are especially important when linking an Amikacin phenotype to AAC (6′)-I aminoglycoside acetyltransferase resistance.

Conclusion & Outlook

Amikacin (BAY416651) combines a defined aminoglycoside mechanism with a resistance profile that is useful but not universal. Its 30S-ribosome activity supports bacterial protein synthesis inhibition studies. Its relative stability against many modifying enzymes supports comparative antibiotic resistance research. AAC (6′)-I-type acetylation remains a documented boundary.

The Guangdong CREC study adds a second layer of context. In that sample, carbapenemase-encoding genes were common, plasmid carriage was frequent, and transfer was observed under the reported conjugation conditions. The appropriate outlook is therefore evidence integration: pair Amikacin phenotyping with gene detection, plasmid analysis, and enzyme-specific interpretation. These approaches can improve mechanistic resolution without overstating what a carbapenemase study or a product specification can prove.

APExBIO is the originating company identified for the B3431 product listing. The Amikacin (BAY416651) Aminoglycoside Antibiotic product page should remain the handling reference for this research reagent. The material is for scientific research use only.